FindTrial
Sign In

To explore the diagnosis of lung cancer by combined serum or thoracic water tumor markers.

To explore the diagnosis of lung cancer by combined serum or thoracic water tumor markers.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015319
Enrollment
Unknown
Registered
2018-03-23
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:histopathology
Index test:Cyfra21-1,&#32
SCC,&#32
PROGRP,&#32
CEA,&#32
HE4,&#32
CA724,&#32
sialic&#32
acid,&#32
d-dimer,&#32
ferritin,&#32
alpha&#32
1-AGP,&#32
hs-crp,&#32
Galectin-3,&#32
ischemia&#32
modified&#32
albumin,&#32
etc.

Sponsors

The Affiliated Suzhou Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. clear disease diagnosis;Lung cancer is characterized by pathology, pneumonia and other diseases, mainly by imaging and serological diagnosis; 2. Aged over 20 years; 3. More than 1 ml of clinical serum samples.

Exclusion criteria

Exclusion criteria: 1. Incomplete data collection of subjects (see 4.2); 2. pregnant; 3. Patients undergoing chemotherapy or radiation therapy.

Design outcomes

Primary

MeasureTime frame
CYFRA 21-1;SCC;PROGRP;CEA;HE4;CA724;—

Secondary

MeasureTime frame
sialic acid;d-dimer;ferritin;a1-AGP;hs-CRP;Galectin-3;ischemia modified albumin;—

Countries

China

Contacts

Public ContactHuang chun

The Affiliated Suzhou Hospital of Nanjing Medical University

1909162354@qq.com+86 13861323156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026